In a time of extreme political divisiveness, when is it the right time, if ever, for the CEO of a public company to speak out publicly about controversial government policies? From immigration reforms that can affect hiring and staffing, to funding changes that can impact grant-supported research, there is no shortage of issues that may warrant a strong point of view in this field. But as a top executive of a life science company, especially a publicly traded company, loud opinions can come with market backlash or alienated employees.
Hear from CEO’s who have taken a bold stand on issues they care about, and learn about the considerations that came along with those decisions. Is it possible to avoid alienating investors and employees? Is not speaking out an even bigger risk? Learn how to navigate this rocky path from the people who have done it, and the experts who advised them.
Ability Level: All
Session ID: 21271